Cargando…

Serum matrix metalloproteinase-3 levels monitor the therapeutic efficacy in Syrian patients with rheumatoid arthritis

BACKGROUND: The plans for the successful treatment of rheumatoid arthritis (RA) seek to attain low disease activity or reach clinical remission. OBJECTIVE: Our study aimed to compare the serum MMP-3 levels with predictors of response to therapy of rheumatoid arthritis in Syrian patients and explore...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hussein, Rama, Aboukhamis, Imad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989645/ https://www.ncbi.nlm.nih.gov/pubmed/36895354 http://dx.doi.org/10.1016/j.heliyon.2023.e14008

Ejemplares similares

The association of serum RANKL levels with disease activity and hematological parameters in Syrian patients with rheumatoid arthritis
por: Hussein, Rama, et al.
Publicado: (2022)

Serum Matrix Metalloproteinase-3 as a Noninvasive Biomarker of Histological Synovitis for Diagnosis of Rheumatoid Arthritis
por: Ma, Jian-Da, et al.
Publicado: (2014)

Serum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis
por: Tokai, Nao, et al.
Publicado: (2018)

Correction: Serum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis
por: Tokai, Nao, et al.
Publicado: (2019)

Matrix metalloproteinase-3 and the 7-joint ultrasound score in the assessment of disease activity and therapeutic efficacy in patients with moderate to severe rheumatoid arthritis
por: Zhou, Ling, et al.
Publicado: (2017)

Matrix Metalloproteinase-9 Level in Synovial Fluid—Association with Joint Destruction in Early Rheumatoid Arthritis
por: Stojanovic, Sonja K., et al.
Publicado: (2023)

Matrix metalloproteinases in rheumatoid arthritis and osteoarthritis: a state of the art review
por: Pulik, Łukasz, et al.
Publicado: (2023)

Two Novel Mutations of the NPM1 Gene in Syrian Adult Patients with Acute Myeloid Leukemia and Normal Karyotype
por: Alarbeed, Ismael F., et al.
Publicado: (2021)

Increased Soluble CD4 in Serum of Rheumatoid Arthritis Patients Is Generated by Matrix Metalloproteinase (MMP)-Like Proteinases
por: Tseng, Wen-Yi, et al.
Publicado: (2013)

Evaluation of the immune feature of ACPA-negative rheumatoid arthritis and the clinical value of matrix metalloproteinase-3
por: Liang, Zhaojun, et al.
Publicado: (2022)

Regulation of serum matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 following rituximab therapy in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor blockers
por: Klimiuk, Piotr Adrian, et al.
Publicado: (2014)

Significance of Circulating and Crevicular Matrix Metalloproteinase-9 in Rheumatoid Arthritis-Chronic Periodontitis Association
por: Silosi, Isabela, et al.
Publicado: (2015)

Matrix Metalloproteinase Gene Activation Resulting from Disordred Epigenetic Mechanisms in Rheumatoid Arthritis
por: Araki, Yasuto, et al.
Publicado: (2017)

Immunomodulatory roles of metalloproteinases in rheumatoid arthritis
por: Bian, Yanqin, et al.
Publicado: (2023)

Serum Matrix Metalloproteinase-3 in Comparison with Acute Phase Proteins as a Marker of Disease Activity and Radiographic Damage in Early Rheumatoid Arthritis
por: Ally, Mahmood M. T. M., et al.
Publicado: (2013)

Lack of association of matrix metalloproteinase-3 gene polymorphism with susceptibility to rheumatoid arthritis: a meta-analysis
por: Feng, Zhitao, et al.
Publicado: (2014)

Alteration of matrix metalloproteinase-3 O-glycan structure as a biomarker for disease activity of rheumatoid arthritis
por: Takeshita, Masaru, et al.
Publicado: (2016)

Serum Level of Matrix Metalloproteinase-3 in Patients with Oral Lichen Planus
por: Farzin, M, et al.
Publicado: (2012)

Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis
por: Pakozdi, Angela, et al.
Publicado: (2006)

CD147 overexpression on synoviocytes in rheumatoid arthritis enhances matrix metalloproteinase production and invasiveness of synoviocytes
por: Zhu, Ping, et al.
Publicado: (2006)

Serum Matrix Metalloproteinase Levels in Patients Exposed to Sulfur Mustard
por: Shohrati, Majid, et al.
Publicado: (2014)

Association between matrix metalloproteinase-1 (MMP-1) protein level and the risk of rheumatoid arthritis and osteoarthritis: a meta-analysis
por: Wang, Maopeng, et al.
Publicado: (2020)

AJAK inhibitor, tofacitinibreduces IL-6 and matrix metalloproteinase-3 productionin rheumatoid arthritis with suppressed cartilage destruction
por: Yamaoka, Kunihiro, et al.
Publicado: (2012)

Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis
por: Li, Yuxuan, et al.
Publicado: (2019)

Continuously elevated serum matrix metalloproteinase-3 for 3 ~ 6 months predict one-year radiographic progression in rheumatoid arthritis: a prospective cohort study
por: Ma, Jian-Da, et al.
Publicado: (2015)

Serum levels of matrix metalloproteinase 2 and matrix metalloproteinase 9 elevated in polypoidal choroidal vasculopathy but not in age-related macular degeneration
por: Zeng, Renpan, et al.
Publicado: (2013)

Robust Therapeutic Efficacy of Matrix Metalloproteinase-2-Cleavable Fas-1-RGD Peptide Complex in Chronic Inflammatory Arthritis
por: Nam, Eon Jeong, et al.
Publicado: (2016)

Changes in Serum Levels of Matrix Metalloproteinase-1 and Tissue Inhibitor of Metalloproteinases-1 in Patients with Essential Hypertension
por: Kostov, Krasimir, et al.
Publicado: (2022)

Serum Level of Matrix Metalloproteinase-9 in Patients with Salivary Gland Tumor
por: Mardani, Maryam, et al.
Publicado: (2014)

Serum matrix metalloproteinase-7 levels in infants with cholestasis and biliary atresia
por: Rohani, Pejman, et al.
Publicado: (2022)

Erratum to: Continuously elevated serum matrix metalloproteinase-3 for 3 ~ 6 months predict one-year radiographic progression in rheumatoid arthritis: a prospective cohort study
por: Ma, Jian-Da, et al.
Publicado: (2015)

Expression of CD147 (EMMPRIN) on neutrophils in rheumatoid arthritis enhances chemotaxis, matrix metalloproteinase production and invasiveness of synoviocytes
por: Wang, Cong-Hua, et al.
Publicado: (2011)

Proteoform Analysis of Matrix Metalloproteinase-9/Gelatinase B and Discovery of Its Citrullination in Rheumatoid Arthritis Synovial Fluids
por: Grillet, Bernard, et al.
Publicado: (2021)

Serum catestatin levels in patients with rheumatoid arthritis
por: Simac, Petra, et al.
Publicado: (2022)

Serum Adropin Levels in Patients with Rheumatoid Arthritis
por: Simac, Petra, et al.
Publicado: (2022)

MicroRNA-4423-3p inhibits proliferation of fibroblast-like synoviocytes by targeting matrix metalloproteinase 13 in rheumatoid arthritis
por: Xu, Weihong, et al.
Publicado: (2021)

Therapeutic Maintenance Level of Methotrexate in Rheumatoid Arthritis: A RBSMR Study
por: Oulkadi, Lamia, et al.
Publicado: (2022)

Serum chemerin and visfatin levels and their ratio as possible diagnostic parameters of rheumatoid arthritis
por: Mohammed Ali, Dunia M., et al.
Publicado: (2020)

Matrix metalloproteinases as therapeutic targets in breast cancer
por: Kwon, Mi Jeong
Publicado: (2023)

The Efficacy of Moxibustion on the Serum Levels of CXCL1 and β-EP in Patients with Rheumatoid Arthritis
por: Tao, Siyu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j43v9562s78nkrasn8jvg1s3pu